4-(4-(4-(2-Fluoroethyl)piperazin-1-yl)piperidin-1-yl)-2-methoxyaniline

Catalog No. :
ACOUKT025
CAS No. :
1089279-63-9
Molecular Formula :
C18H29FN4O
Molecular Weight :
336.45

IUPAC Name:4-(4-(4-(2-fluoroethyl)piperazin-1-yl)piperidin-1-yl)-2-methoxyaniline

4-(4-(4-(2-Fluoroethyl)piperazin-1-yl)piperidin-1-yl)-2-methoxyaniline structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg97%$134.00Login to see priceInquiryInquiry
250mg97%$231.00Login to see priceInquiryInquiry
1g97%$494.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-(4-(4-(2-Fluoroethyl)piperazin-1-yl)piperidin-1-yl)-2-methoxyaniline
IUPAC Name4-(4-(4-(2-fluoroethyl)piperazin-1-yl)piperidin-1-yl)-2-methoxyaniline
Molecular FormulaC18H29FN4O
Molecular Weight336.45
SMILESNC1=CC=C(N2CCC(N3CCN(CCF)CC3)CC2)C=C1OC
InChI KeyHXJLMYXPDIHNFA-UHFFFAOYSA-N
Synonym4-(4-(4-(2-fluoroethyl)piperazin-1-yl)piperidin-1-yl)-2-methoxyaniline;4-[4-[4-(2-Fluoroethyl)-1-piperazinyl]-1-piperidinyl]-2-(methyloxy)aniline;Benzenamine, 4-[4-[4-(2-fluoroethyl)-1-piperazinyl]-1-piperidinyl]-2-methoxy-
CAS No.1089279-63-9

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACOUKT025 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACOUKT025 route product structure diagram
    ACOUKT0251089279-63-9
Inquiry

2. ACOUKT025 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACAJLS549 route compound structure diagram
    ACAJLS549541505-04-8 In Stock
  4. Then
  5. ACOUKT025 route product structure diagram
    ACOUKT0251089279-63-9
Inquiry

Comments (0)